A Pilot Study of Neoadjuvant sEphB4-HSA in Patients With Genitourinary Cancers
Phase of Trial: Phase I
Latest Information Update: 19 Jun 2018
At a glance
- Drugs SEphB4-HSA (Primary)
- Indications Bladder cancer; Prostate cancer; Renal cancer; Renal cell carcinoma; Urogenital cancer
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 08 Jun 2018 Planned primary completion date changed from 2 Aug 2018 to 2 Aug 2019.
- 08 Jun 2018 Planned End Date changed from 2 Aug 2019 to 2 Aug 2020.